Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 884.54 USD 2.89% Market Closed
Market Cap: 838.5B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is hidden USD. Compared to the current market price of 884.54 USD, Eli Lilly and Co is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

18.6
P/S
P/S
Price to Sales
18.6
vs History
19
vs Industry
9
Median 3Y
16.1
Median 5Y
10.4
Industry
2.4
Forward
13.9
More Details
79.1
P/E
P/E
Price to Earnings
79.1
vs History
26
vs Industry
5
Median 3Y
72.1
Median 5Y
51.3
Industry
20.6
Forward
38.1
More Details
95
P/OCF
P/OCF
Price to OCF
95
vs History
22
vs Industry
5
Median 3Y
86.5
Median 5Y
40.3
Industry
15.5
More Details
94.9
P/FCFE
P/FCFE
Price to FCFE
94.9
vs History
26
vs Industry
5
Median 3Y
87
Median 5Y
51.9
Industry
23
More Details
59.1
P/B
P/B
Price to Book Value
59.1
vs History
12
vs Industry
0
Median 3Y
46.5
Median 5Y
35.3
Industry
1.9
More Details
19.2
EV/S
EV/S
Enterprise Value to Sales
19.2
vs History
19
vs Industry
8
Median 3Y
16.6
Median 5Y
10.8
Industry
2.5
Forward
14.4
More Details
23.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
23.6
vs History
20
vs Industry
9
Median 3Y
20.7
Median 5Y
14.2
Industry
4.9
More Details
45.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
45.9
vs History
33
vs Industry
7
Median 3Y
47.2
Median 5Y
30.8
Industry
12.6
Forward
30.9
More Details
50.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
50.7
vs History
33
vs Industry
8
Median 3Y
54.1
Median 5Y
36.7
Industry
15.7
Forward
33.5
More Details
97.9
EV/OCF
EV/OCF
Enterprise Value to OCF
97.9
vs History
22
vs Industry
5
Median 3Y
89.4
Median 5Y
41.9
Industry
14
More Details
2 083.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
2 083.6
vs History
1
vs Industry
0
Median 3Y
58.6
Median 5Y
45.2
Industry
17.7
More Details
12
EV/IC
EV/IC
Enterprise Value to IC
12
vs History
14
vs Industry
8
Median 3Y
9.8
Median 5Y
7.3
Industry
1.8
More Details

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
US
Pfizer Inc
NYSE:PFE
129.9B USD 2 16.2 8 11.3
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 25.1
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
US
Pfizer Inc
NYSE:PFE
16.2
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 395.1
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
US
Pfizer Inc
NYSE:PFE
8
3%
2.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 698.5
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4
US
Pfizer Inc
NYSE:PFE
11.3
10%
1.1

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.